Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer.
Authors
Carter, LouiseRothwell, Dominic G
Mesquita, Barbara
Smowton, Christopher
Leong, Hui Sun
Fernandez-Gutierrez, Fabiola
Li, Yaoyong
Burt, Deborah J
Antonello, Jenny
Morrow, Christopher J
Hodgkinson, Cassandra L
Morris, Karen
Priest, Lynsey
Carter, Mathew
Miller, Crispin J
Hughes, A
Blackhall, Fiona H
Dive, Caroline
Brady, Ged
Affiliation
Clinical and Experimental Pharmacology Group, CRUK Manchester Institute, University of Manchester, Manchester, UKIssue Date
2016-11-21
Metadata
Show full item recordAbstract
In most patients with small-cell lung cancer (SCLC)-a metastatic, aggressive disease-the condition is initially chemosensitive but then relapses with acquired chemoresistance. In a minority of patients, however, relapse occurs within 3 months of initial treatment; in these cases, disease is defined as chemorefractory. The molecular mechanisms that differentiate chemosensitive from chemorefractory disease are currently unknown. To identify genetic features that distinguish chemosensitive from chemorefractory disease, we examined copy-number aberrations (CNAs) in circulating tumor cells (CTCs) from pretreatment SCLC blood samples. After analysis of 88 CTCs isolated from 13 patients (training set), we generated a CNA-based classifier that we validated in 18 additional patients (testing set, 112 CTC samples) and in six SCLC patient-derived CTC explant tumors. The classifier correctly assigned 83.3% of the cases as chemorefractory or chemosensitive. Furthermore, a significant difference was observed in progression-free survival (PFS) (Kaplan-Meier P value = 0.0166) between patients designated as chemorefractory or chemosensitive by using the baseline CNA classifier. Notably, CTC CNA profiles obtained at relapse from five patients with initially chemosensitive disease did not switch to a chemorefractory CNA profile, which suggests that the genetic basis for initial chemoresistance differs from that underlying acquired chemoresistance.Citation
Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. 2016 Nat MedJournal
Nature MedicineDOI
10.1038/nm.4239PubMed ID
27869802Type
ArticleLanguage
enISSN
1546-170Xae974a485f413a2113503eed53cd6c53
10.1038/nm.4239
Scopus Count
Collections
Related articles
- Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells.
- Authors: Su Z, Wang Z, Ni X, Duan J, Gao Y, Zhuo M, Li R, Zhao J, Ma Q, Bai H, Chen H, Wang S, Chen X, An T, Wang Y, Tian Y, Yu J, Wang D, Xie XS, Bai F, Wang J
- Issue date: 2019 Aug 15
- Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.
- Authors: Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K, Pepper SD, Nonaka D, Greystoke A, Kelly P, Bola B, Krebs MG, Antonello J, Ayub M, Faulkner S, Priest L, Carter L, Tate C, Miller CJ, Blackhall F, Brady G, Dive C
- Issue date: 2014 Aug
- Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
- Authors: Shen J, Zhao J, Jiang T, Li X, Zhao C, Su C, Zhou C
- Issue date: 2017 Jul 25
- Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer.
- Authors: Zhang J, Tian C, Lv F, Wang J, Han W, Nie J, Dai L, Hu W, Chen X, Ma X, Tian G, Wu D, Han S, Wang Y, Long J, Zhang Z, Fang J, Zhang H
- Issue date: 2019 Apr 18
- Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
- Authors: Zhu HH, Liu YT, Feng Y, Zhang LN, Zhang TM, Dong GL, Xing PY, Wang HY, Shi YK, Hu XS
- Issue date: 2021 Oct